Could a cancer drug let some patients skip surgery?
NCT ID NCT07409844
First seen Feb 15, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests whether giving the immunotherapy drug pembrolizumab before planned surgery can shrink or eliminate tumors in people with a specific type of colon cancer (dMMR). About 152 participants with stage I to III colon cancer will receive different doses of the drug. If scans and exams show no cancer left, they may avoid surgery and instead be closely monitored. If cancer remains, standard surgery and possibly chemotherapy will follow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zealand University Hospital
Køge, 4600, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.